Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AssigneeCureTech Ltd. and Mor-Research Applications Ltd.
InventorsBritta Hardy, Steven Tarran Jones, Leah Klapper
Life of this patent
Estimating the term…
Abstract
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.
Claims19
A method of inducing proliferative activity of lymphocytes, particularly CD4+ T cells, comprising administering to an individual in need thereof and having an immune deficiency, a pharmaceutical composition comprising an effective amount of humanized monoclonal antibodies having at least one complementarity determining region (CDR) of murine monoclonal antibody BAT-1 (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom, wherein the humanized antibody retains the anti-tumor activity of mBAT-1 monoclonal antibody and comprises:
- a light chain variable region selected from the group consisting of:
- BATRKA (SEQ ID NO:
- 15), BATRKB (SEQ ID NO:
- 16), BATRKC (SEQ ID NO:
- 17), and BATRKD (SEQ ID NO:
- 18), and
- a heavy chain variable region selected from the group consisting of:
- BATRHA (SEQ ID NO:
- 20), BATRHB (SEQ ID NO:
- 21), BATRHC (SEQ ID NO:
- 22), BATRHD (SEQ ID NO:
- 23) and BATRHE (SEQ ID NO:
- 24).
A method of inducing cytolytic activity of lymphocytes, particularly of CD4+ T cells, comprising administering to an individual in need thereof and having an immune deficiency, a pharmaceutical composition comprising an effective amount of humanized monoclonal antibodies having at least one complementarity determining region (CDR) of murine monoclonal antibody BAT-1 (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom, wherein the humanized antibody retains the anti-tumor activity of mBAT-1 monoclonal antibody and comprises:
- a light chain variable region selected from the group consisting of:
- BATRKA (SEQ ID NO:
- 15), BATRKB (SEQ ID NO:
- 16), BATRKC (SEQ ID NO:
- 17), and BATRKD (SEQ ID NO:
- 18), and
- a heavy chain variable region selected from the group consisting of:
- BATRHA (SEQ ID NO:
- 20), BATRHB (SEQ ID NO:
- 21), BATRHC (SEQ ID NO:
- 22), BATRHD (SEQ ID NO:
- 23) and BATRHE (SEQ ID NO:
- 24).
A method of inducing stimulatory activity of lymphocytes, particularly CD4+ T cells, comprising administering to an individual in need thereof and having an immune deficiency, a pharmaceutical composition comprising an effective amount of humanized monoclonal antibodies having at least one complementarity determining region (CDR) of murine monoclonal antibody BAT-1 (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom, wherein the humanized antibody retains the anti-tumor activity of mBAT-1 monoclonal antibody and comprises:
- a light chain variable region selected from the group consisting of:
- BATRKA (SEQ ID NO:
- 15), BATRKB (SEQ ID NO:
- 16), BATRKC (SEQ ID NO:
- 17), and BATRKD (SEQ ID NO:
- 18), and
- a heavy chain variable region selected from the group consisting of:
- BATRHA (SEQ ID NO:
- 20), BATRHB (SEQ ID NO:
- 21), BATRHC (SEQ ID NO:
- 22), BATRHD (SEQ ID NO:
- 23) and BATRHE (SEQ ID NO:
- 24).
A method of increasing the survival of activated CD4+ T cells comprising administering to an individual in need thereof and having an immune deficiency, a pharmaceutical composition comprising an effective amount of humanized monoclonal antibodies having at least one complementarity determining region (CDR) of murine monoclonal antibody BAT-1 (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom, wherein the humanized antibody retains the anti-tumor activity of mBAT-1 monoclonal antibody and comprises:
- a light chain variable region selected from the group consisting of:
- BATRKA (SEQ ID NO:
- 15), BATRKB (SEQ ID NO:
- 16), BATRKC (SEQ ID NO:
- 17), and BATRKD (SEQ ID NO:
- 18), and
- a heavy chain variable region selected from the group consisting of:
- BATRHA (SEQ ID NO:
- 20), BATRHB (SEQ ID NO:
- 21), BATRHC (SEQ ID NO:
- 22), BATRHD (SEQ ID NO:
- 23) and BATRHE (SEQ ID NO:
- 24).
A method of increasing the survival of activated CD4+ T cells comprising contacting the activated T cells with a pharmaceutical composition comprising an effective amount of humanized monoclonal antibodies having at least one complementarity determining region (CDR) of murine monoclonal antibody BAT-1 (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom, wherein the humanized antibody retains the anti-tumor activity of mBAT-1 monoclonal antibody.
Dependencies are inferred from the claim text.